We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.


Magnetic resonance imaging in the management of prolactinomas; a review of the evidence



This review aimed to evaluate data on the use of magnetic resonance imaging in the management of prolactinomas.


Recent literature about prolactinoma behavior and magnetic resonance imaging in the management of prolactinomas is reviewed.


A review of evidence regarding prolactinoma pituitary MRI follow-up; techniques and sequences, recent data on possible gadolinium retention, the role and a review of T2-weighted images in the identification of prolactinomas and frequently encountered clinical scenarios, as well as MRI correlation with prolactin secretion, tumor growth and prediction of response to medical therapy are presented.


The underlying decision to perform serial imaging in prolactinoma patients should be individualized on a case-by-case basis. Future studies should focus on alternative imaging methods and/or contract agents.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5


  1. 1.

    Eroukhmanoff J, Tejedor I, Potorac I, Cuny T, Bonneville JF, Dufour H, Weryha G, Beckers A, Touraine P, Brue T, Castinetti F (2017) MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. Eur J Endocrinol 176(3):323–328. https://doi.org/10.1530/EJE-16-0897

  2. 2.

    Bladowska J, Biel A, Zimny A, Lubkowska K, Bednarek-Tupikowska G, Sozanski T, Zaleska-Dorobisz U, Sasiadek M (2011) Are T2-weighted images more useful than T1-weighted contrast-enhanced images in assessment of postoperative sella and parasellar region? Med Sci Monit 17(10), MT83-MT90. https://doi.org/10.12659/msm.881966

  3. 3.

    Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine S (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288. https://doi.org/10.1210/jc.2010-1692

  4. 4.

    McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH, Jacobs PM, Lenkinski RE, Maravilla KR, Prince MR, Rowley HA, Tweedle MF, Kressel HY (2018) Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology 289(2):517–534. https://doi.org/10.1148/radiol.2018181151

  5. 5.

    Dekkers IA, Roos R, van der Molen AJ (2018) Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol 28(4):1579–1584. https://doi.org/10.1007/s00330-017-5065-8

  6. 6.

    Moreno J, Vaz N, Soler J, Carrasco J, Podlipnick S (2018) High signal intensity in the dentate nucleus on unenhanced T1-weighted MR images in melanoma patients receiving macrocyclic gadolinium-based contrast. J Radiol Diagn Methods 1:101–107

  7. 7.

    Nachtigall LB, Karavitaki N, Kiseljak-Vassiliades K, Ghalib L, Fukuoka H, Syro LV, Kelly D, Fleseriu M (2019) Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey. Pituitary 22(1):37–45. https://doi.org/10.1007/s11102-018-0924-0

  8. 8.

    Yuksekkaya R, Aggunlu L, Oner Y, Celik H, Akpek S, Celikyay F (2014) Assessment of t2-weighted coronal magnetic resonance images in the investigation of pituitary lesions. ISRN Radiol 2014:650926. https://doi.org/10.1155/2014/650926

  9. 9.

    Burlacu MC, Maiter D, Duprez T, Delgrange E (2019) T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Endocrine 63(2):323–331. https://doi.org/10.1007/s12020-018-1765-3

  10. 10.

    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85(6):2247–2252. https://doi.org/10.1210/jcem.85.6.6657

  11. 11.

    Lombardi M, Lupi I, Cosottini M, Rossi G, Manetti L, Raffaelli V, Sardella C, Martino E, Bogazzi F (2014) Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma. Horm Metab Res 46(13):939–942. https://doi.org/10.1055/s-0034-1389925

  12. 12.

    Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11):3574–3579. https://doi.org/10.1210/jcem.82.11.4368

  13. 13.

    Molitch ME (2014) Management of medically refractory prolactinoma. J Neurooncol 117(3):421–428. https://doi.org/10.1007/s11060-013-1270-8

  14. 14.

    Akinduro OO, Lu VM, Izzo A, De Biase G, Vilanilam G, Van Gompel JJ, Bernet V, Donaldson A, Olomu O, Meyer FB, Quinones-Hinojosa A, Chaichana KL (2019) Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure. World Neurosurg. https://doi.org/10.1016/j.wneu.2019.05.249

  15. 15.

    Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60(4):698–705. https://doi.org/10.1210/jcem-60-4-698

  16. 16.

    Araujo C, Marques O, Almeida R, Santos MJ (2018) Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses. Endocrine 62(2):470–476. https://doi.org/10.1007/s12020-018-1703-4

  17. 17.

    Jamrozik SI, Bennet AP, James-Deidier A, Tremollieres F, Saint-Martin F, Dumoulin S, Valat-Coustols M, de Glisezinski I, Tremoulet M, Manelfe C, Louvet JP (1996) Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients. J Endocrinol Invest 19(7):472–479. https://doi.org/10.1007/bf03349893

  18. 18.

    Alkabbani AG, Mon SY, Hatipoglu B, Kennedy L, Faiman C, Weil RJ, Hamrahian AH (2014) Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth? Pituitary 17(2):97–102. https://doi.org/10.1007/s11102-013-0473-5

  19. 19.

    Kupersmith MJ, Kleinberg D, Warren FA, Budzilovitch G, Cooper P (1989) Growth of prolactinoma despite lowering of serum prolactin by bromocriptine. Neurosurgery 24(3):417–423. https://doi.org/10.1227/00006123-198903000-00020

  20. 20.

    Saeki N, Nakamura M, Sunami K, Yamaura A (1998) Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocr J 45(4):529–537. https://doi.org/10.1507/endocrj.45.529

  21. 21.

    Schlechte JA (2007) Long-term management of prolactinomas. J Clin Endocrinol Metab 92(8):2861–2865. https://doi.org/10.1210/jc.2007-0836

  22. 22.

    Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, Sanfilippo J, Webster J, Zacur H (1999) Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 44(12 Suppl):1075–1084

  23. 23.

    Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94(7):2428–2436. https://doi.org/10.1210/jc.2008-2103

  24. 24.

    Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86(11):5256–5261. https://doi.org/10.1210/jcem.86.11.8054

  25. 25.

    Watanabe S, Akutsu H, Takano S, Yamamoto T, Ishikawa E, Suzuki H, Matsumura A (2017) Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal. Clin Endocrinol (Oxf) 86(2):207–213. https://doi.org/10.1111/cen.13240

  26. 26.

    Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349(21):2023–2033. https://doi.org/10.1056/NEJMoa022657

  27. 27.

    Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63(1):26–31. https://doi.org/10.1111/j.1365-2265.2005.02293.x

  28. 28.

    Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22(5):354–359. https://doi.org/10.1007/BF03343573

  29. 29.

    Passos VQ, Souza JJ, Musolino NR, Bronstein MD (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87(8):3578–3582. https://doi.org/10.1210/jcem.87.8.8722

  30. 30.

    Molitch ME (1999) Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 28(1):143–169

  31. 31.

    Orrego JJ, Chandler WF, Barkan AL (2000) Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary 3(3):189–192

  32. 32.

    Thorner MO, Perryman RL, Rogol AD, Conway BP, Macleod RM, Login IS, Morris JL (1981) Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 53(3):480–483. https://doi.org/10.1210/jcem-53-3-480

  33. 33.

    March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML, Marrs RP, Mishell DR Jr (1981) Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139(7):835–844. https://doi.org/10.1016/0002-9378(81)90553-6

  34. 34.

    Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68(2):412–418. https://doi.org/10.1210/jcem-68-2-412

  35. 35.

    Klibanski A (2010) Clinical practice Prolactinomas. N Engl J Med 362(13):1219–1226. https://doi.org/10.1056/NEJMcp0912025

  36. 36.

    Corenblum B, Donovan L (1993) The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 59(3):671–673. https://doi.org/10.1016/s0015-0282(16)55819-1

  37. 37.

    Testa G, Vegetti W, Motta T, Alagna F, Bianchedi D, Carlucci C, Bianchi M, Parazzini F, Crosignani PG (1998) Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58(2):69–73

  38. 38.

    Santharam S, Fountas A, Tampourlou M, Arlt W, Ayuk J, Gittoes N, Toogood A, Karavitaki N (2018) Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol (Oxf) 89(3):346–353. https://doi.org/10.1111/cen.13765

  39. 39.

    Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109:1–9. https://doi.org/10.1159/000495775

  40. 40.

    Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521–535. https://doi.org/10.1007/s00401-017-1769-8

  41. 41.

    Berezin M, Shimon I, Hadani M (1995) Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Invest 18(6):436–441. https://doi.org/10.1007/BF03349742

  42. 42.

    Iglesias P, Bernal C, Villabona C, Castro JC, Arrieta F, Diez JJ (2012) Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome. Clin Endocrinol (Oxf) 77(2):281–287. https://doi.org/10.1111/j.1365-2265.2012.04351.x

  43. 43.

    Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102–2107. https://doi.org/10.1210/jcem.82.7.4088

  44. 44.

    Calle-Rodrigue RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH (1998) Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73(11):1046–1052. https://doi.org/10.4065/73.11.1046

  45. 45.

    Delgrange E, Daems T, Verhelst J, Abs R, Maiter D (2009) Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160(5):747–752. https://doi.org/10.1530/EJE-09-0012

  46. 46.

    Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325–331

  47. 47.

    Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85(9):3053–3057. https://doi.org/10.1210/jcem.85.9.6798

  48. 48.

    Qu X, Wang M, Wang G, Han T, Mou C, Han L, Jiang M, Qu Y, Zhang M, Pang Q, Xu G (2011) Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur J Endocrinol 164(4):499–504. https://doi.org/10.1530/EJE-10-0961

  49. 49.

    Liu W, Zahr RS, McCartney S, Cetas JS, Dogan A, Fleseriu M (2018) Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. Pituitary 21(5):454–462. https://doi.org/10.1007/s11102-018-0898-y

  50. 50.

    Faje A, Chunharojrith P, Nency J, Biller BM, Swearingen B, Klibanski A (2016) Dopamine agonists can reduce cystic prolactinomas. J Clin Endocrinol Metab 101(10):3709–3715. https://doi.org/10.1210/jc.2016-2008

  51. 51.

    Shimon I (2019) Giant prolactinomas. Neuroendocrinology 109(1):51–56. https://doi.org/10.1159/000495184

  52. 52.

    Hamidi O, Van Gompel J, Gruber L, Kittah NE, Donegan D, Philbrick KA, Koeller KK, Erickson D, Natt N, Nippoldt TB, Young WF Jr, Bancos I (2019) Management and outcomes of giant prolactinoma: a series of 71 patients. Endocr Pract 25(4):340–352. https://doi.org/10.4158/EP-2018-0392

  53. 53.

    Maiter D, Delgrange E (2014) Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 170(6):R213–227. https://doi.org/10.1530/EJE-14-0013

  54. 54.

    Delgrange E, Raverot G, Bex M, Burman P, Decoudier B, Devuyst F, Feldt-Rasmussen U, Andersen M, Maiter D (2014) Giant prolactinomas in women. Eur J Endocrinol 170(1):31–38. https://doi.org/10.1530/EJE-13-0503

  55. 55.

    Lv L, Hu Y, Yin S, Zhou P, Yang Y, Ma W, Zhang S, Wang X, Jiang S (2019) Giant prolactinomas: outcomes of multimodal treatments for 42 cases with long-term follow-up. Exp Clin Endocrinol Diabetes 127(5):295–302. https://doi.org/10.1055/a-0597-8877

  56. 56.

    Primeau V, Raftopoulos C, Maiter D (2012) Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 166(5):779–786. https://doi.org/10.1530/EJE-11-1000

  57. 57.

    Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158(1):11–18. https://doi.org/10.1530/EJE-07-0248

  58. 58.

    Serri O, Rasio E, Beauregard H, Hardy J, Somma M (1983) Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 309(5):280–283. https://doi.org/10.1056/NEJM198308043090505

  59. 59.

    Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1):71–83. https://doi.org/10.1007/s11102-011-0347-7

  60. 60.

    Schlechte JA, Sherman BM, Chapler FK, VanGilder J (1986) Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J Clin Endocrinol Metab 62(6):1296–1301. https://doi.org/10.1210/jcem-62-6-1296

  61. 61.

    Cohen-Inbar O, Xu Z, Schlesinger D, Vance ML, Sheehan JP (2015) Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary 18(6):820–830. https://doi.org/10.1007/s11102-015-0658-1

  62. 62.

    Pouratian N, Sheehan J, Jagannathan J, Laws ER Jr, Steiner L, Vance ML (2006) Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 59(2):255–266. https://doi.org/10.1227/01.NEU.0000223445.22938.BD. (discussion 255–266)

  63. 63.

    Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW (2000) Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg 93(Suppl 3):10–13. https://doi.org/10.3171/jns.2000.93.supplement

  64. 64.

    Kleinberg DL, Noel GL, Frantz AG (1977) Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med 296(11):589–600. https://doi.org/10.1056/NEJM197703172961103

  65. 65.

    Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534. https://doi.org/10.1210/er.2005-9998

  66. 66.

    Molitch ME (2006) Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 35(1):99–116. https://doi.org/10.1016/j.ecl.2005.09.011

  67. 67.

    Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf) 73(2):236–242. https://doi.org/10.1111/j.1365-2265.2010.03808.x

  68. 68.

    Maiter D (2016) Prolactinoma and pregnancy: from the wish of conception to lactation. Ann Endocrinol (Paris) 77(2):128–134. https://doi.org/10.1016/j.ando.2016.04.001

  69. 69.

    Almalki MH, Ur E, Johnson M, Clarke DB, Imran SA (2012) Management of prolactinomas during pregnancy—a survey of four Canadian provinces. Clin Invest Med 35(2):E96–104

  70. 70.

    Domingue ME, Devuyst F, Alexopoulou O, Corvilain B, Maiter D (2014) Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol (Oxf) 80(5):642–648. https://doi.org/10.1111/cen.12370

  71. 71.

    Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M, Pivonello R, Colao A (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98(1):372–379. https://doi.org/10.1210/jc.2012-3039

  72. 72.

    Bashari WA, Senanayake R, Fernandez-Pombo A, Gillett D, Koulouri O, Powlson AS, Matys T, Scoffings D, Cheow H, Mendichovszky I, Gurnell M (2019) Modern imaging of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. https://doi.org/10.1016/j.beem.2019.05.002

  73. 73.

    Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2):533–538. https://doi.org/10.1148/radiol.2282020695

  74. 74.

    Tosaka M, Sato N, Hirato J, Fujimaki H, Yamaguchi R, Kohga H, Hashimoto K, Yamada M, Mori M, Saito N, Yoshimoto Y (2007) Assessment of hemorrhage in pituitary macroadenoma by T2*-weighted gradient-echo MR imaging. AJNR Am J Neuroradiol 28(10):2023–2029. https://doi.org/10.3174/ajnr.A0692

  75. 75.

    Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, Marti C, Halperin I, Webb SM (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 95(11):4973–4978. https://doi.org/10.1210/jc.2010-0573

  76. 76.

    Potorac I, Petrossians P, Daly AF, Schillo F, Ben Slama C, Nagi S, Sahnoun M, Brue T, Girard N, Chanson P, Nasser G, Caron P, Bonneville F, Raverot G, Lapras V, Cotton F, Delemer B, Higel B, Boulin A, Gaillard S, Luca F, Goichot B, Dietemann JL, Beckers A, Bonneville JF (2015) Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer 22(2):169–177. https://doi.org/10.1530/ERC-14-0305

  77. 77.

    Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, Bollerslev J (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf) 77(1):72–78. https://doi.org/10.1111/j.1365-2265.2011.04286.x

  78. 78.

    Heck A, Emblem KE, Casar-Borota O, Ringstad G, Bollerslev J (2016) MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine 53(1):327–330. https://doi.org/10.1007/s12020-015-0816-2

  79. 79.

    Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52(2):333–343. https://doi.org/10.1007/s12020-015-0766-8

  80. 80.

    Coopmans EC, van der Lely AJ, Schneiders JJ, Neggers S (2019) Potential antitumour activity of pasireotide on pituitary tumours in acromegaly. Lancet Diabetes Endocrinol 7(6):425–426. https://doi.org/10.1016/S2213-8587(19)30113-5

  81. 81.

    Dogansen SC, Yalin GY, Tanrikulu S, Tekin S, Nizam N, Bilgic B, Sencer S, Yarman S (2018) Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary 21(4):347–354. https://doi.org/10.1007/s11102-018-0877-3

  82. 82.

    Bahuleyan B, Raghuram L, Rajshekhar V, Chacko AG (2006) To assess the ability of MRI to predict consistency of pituitary macroadenomas. Br J Neurosurg 20(5):324–326. https://doi.org/10.1080/02688690601000717

  83. 83.

    Iuchi T, Saeki N, Tanaka M, Sunami K, Yamaura A (1998) MRI prediction of fibrous pituitary adenomas. Acta Neurochir (Wien) 140(8):779–786

  84. 84.

    Zeynalova A, Kocak B, Durmaz ES, Comunoglu N, Ozcan K, Ozcan G, Turk O, Tanriover N, Kocer N, Kizilkilic O, Islak C (2019) Preoperative evaluation of tumour consistency in pituitary macroadenomas: a machine learning-based histogram analysis on conventional T2-weighted MRI. Neuroradiology 61(7):767–774. https://doi.org/10.1007/s00234-019-02211-2

  85. 85.

    Yiping L, Ji X, Daoying G, Bo Y (2016) Prediction of the consistency of pituitary adenoma: a comparative study on diffusion-weighted imaging and pathological results. J Neuroradiol 43(3):186–194. https://doi.org/10.1016/j.neurad.2015.09.003

  86. 86.

    Bonneville J-F, Bonneville F, Cattin F, Nagi S (2016) MRI of the pituitary gland. Springer, Switzerland

  87. 87.

    Levine SN, Ishaq S, Nanda A, Wilson JD, Gonzalez-Toledo E (2013) Occurrence of extensive spherical amyloid deposits in a prolactin-secreting pituitary macroadenoma: a radiologic-pathologic correlation. Ann Diagn Pathol 17(4):361–366. https://doi.org/10.1016/j.anndiagpath.2013.03.001

  88. 88.

    Kreutz J, Vroonen L, Cattin F, Petrossians P, Thiry A, Rostomyan L, Tshibanda L, Beckers A, Bonneville JF (2015) Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology 57(7):679–684. https://doi.org/10.1007/s00234-015-1519-3

Download references

Author information

Correspondence to Maria Fleseriu.

Ethics declarations

Conflict of interest

All the authors declared that they have no conflict of interest.

Research involving human participants or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Varlamov, E.V., Hinojosa-Amaya, J.M. & Fleseriu, M. Magnetic resonance imaging in the management of prolactinomas; a review of the evidence. Pituitary 23, 16–26 (2020). https://doi.org/10.1007/s11102-019-01001-6

Download citation


  • Prolactinoma
  • Magnetic resonance imaging
  • T2-weighted
  • Gadolinium
  • Lactotroph adenoma